358 Participants Needed

Bulking Agent vs Sling for Stress Urinary Incontinence

(BASIS Trial)

Recruiting at 8 trial locations
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: NICHD Pelvic Floor Disorders Network
Must be taking: OAB/UUI medications
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on stable medication for overactive bladder or urinary urgency incontinence, you should continue it without changes for at least 3 months before the trial and throughout the study period.

What data supports the effectiveness of the treatment Bulkamid Transurethral Bulking Agent for stress urinary incontinence?

Bulkamid, a gel used to treat stress urinary incontinence, has shown long-term effectiveness and safety, with studies reporting success rates between 64% and 74%. It is a minimally invasive option that creates a supportive mass in the urethra, and is often used when other treatments like midurethral slings are not suitable or have failed.12345

Is Bulkamid safe for treating stress urinary incontinence?

Bulkamid, a bulking agent used for stress urinary incontinence, is considered safe and minimally invasive, with high tissue compatibility and fewer risks of complications like erosion or migration compared to other particulate agents.14567

How is the Bulkamid Transurethral Bulking Agent and Solyx Single-incision Sling treatment different from other treatments for stress urinary incontinence?

The Bulkamid Transurethral Bulking Agent and Solyx Single-incision Sling treatment is unique because it combines a bulking agent, which is injected to add volume and support to the urethra, with a minimally invasive sling procedure that provides additional support to prevent urine leakage. This dual approach offers a less invasive alternative to traditional surgeries and may provide longer-lasting results compared to treatments that require frequent re-injections.89101112

What is the purpose of this trial?

This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.The Primary Aim is to determine the comparative effectiveness (as defined by "much" or "very much" better on PGI-I) of transurethral bulking agent (TBA) \[for 1 or 2 injections in 12 months\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).

Research Team

EL

Emily Lukacz, MD

Principal Investigator

University of California, San Diego

MG

Marie Gantz, MD

Principal Investigator

RTI International

Eligibility Criteria

This trial is for women who have stress urinary incontinence (SUI) or mixed urinary incontinence with a stress component, and haven't found relief from conservative treatments. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and agree to follow the study procedures.

Inclusion Criteria

I have tried or cannot do basic treatments for urinary incontinence.
Available for up to 3 years
Agrees to randomization
See 4 more

Exclusion Criteria

My vaginal prolapse extends beyond the hymen.
Pregnant, breastfeeding, or plans for pregnancy within 1 year
Incomplete emptying (PVR greater than 150mL)
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either transurethral bulking agent or single-incision sling as treatment for stress urinary incontinence

12 months
1 visit (in-person) for procedure, follow-up visits at 2-4 weeks, 3 months, and 12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

36 months
Follow-up visits at 6 months, 24 months, and 36 months (phone)

Treatment Details

Interventions

  • Bulkamid Transurethral Bulking Agent
  • Solyx Single-incision Sling
Trial Overview The trial is testing two different treatments for SUI: Bulkamid Transurethral Bulking Agent injections versus the Solyx Single-incision Sling procedure. It's designed to see which one is more effective at improving symptoms after 12 months.
Participant Groups
2Treatment groups
Active Control
Group I: Solyx Single-incision SlingActive Control1 Intervention
Solyx Single-incision Sling
Group II: Bulkamid Transurethral Bulking AgentActive Control1 Intervention
Bulkamid Transurethral Bulking Agent

Bulkamid Transurethral Bulking Agent is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Bulkamid for:
  • Stress urinary incontinence
🇺🇸
Approved in United States as Bulkamid for:
  • Stress urinary incontinence
🇨🇦
Approved in Canada as Bulkamid for:
  • Stress urinary incontinence

Find a Clinic Near You

Who Is Running the Clinical Trial?

NICHD Pelvic Floor Disorders Network

Lead Sponsor

Trials
16
Recruited
4,900+

Kaiser Permanente

Collaborator

Trials
563
Recruited
27,400,000+

RTI International

Collaborator

Trials
201
Recruited
942,000+

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator

Trials
2,103
Recruited
2,760,000+

Duke University

Collaborator

Trials
2,495
Recruited
5,912,000+

University of Texas Southwestern Medical Center

Collaborator

Trials
1,102
Recruited
1,077,000+

University of Chicago

Collaborator

Trials
1,086
Recruited
844,000+

University of California, San Diego

Collaborator

Trials
1,215
Recruited
1,593,000+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Women and Infants Hospital of Rhode Island

Collaborator

Trials
119
Recruited
59,200+

Findings from Research

In a study of 1,200 women treated with Bulkamid for stress urinary incontinence (SUI) or mixed urinary incontinence (MUI), 67.1% reported feeling cured or improved after 7 years, indicating long-term efficacy of this treatment.
The procedure was found to be safe, with only transient postoperative complications, and significant improvements in quality of life and incontinence symptoms, as evidenced by a reduction in ICIQ-UI SF scores and a mean increase in VAS QoL scores.
Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence.Brosche, T., Kuhn, A., Lobodasch, K., et al.[2023]
Bulkamid® is a nonbiodegradable urethral bulking agent that can be injected in an office setting under local anesthesia, making it a minimally invasive treatment for women with recurrent stress urinary incontinence (SUI).
The procedure has minimal downtime and only minor potential complications, positioning Bulkamid® as a valid treatment option for patients who have not found success with midurethral sling (MUS) surgeries.
Urethral Bulkamid® injection after failed midurethral sling: a step-by-step video.Lukanović, D., Blaganje, M., Rhazi, I., et al.[2023]
Midurethral slings are highly effective for treating stress urinary incontinence (SUI), with success rates up to 80%, while bulking agents have a lower efficacy of 64% to 74% but are associated with fewer complications.
This study will assess patient satisfaction and preferences between midurethral slings and bulking agents in a non-randomized trial involving 266 patients, aiming to provide insights into the role of bulking agents as a first-choice treatment option.
Comparing Single-Incision Midurethral Sling with Bulking Agents for Female Stress Urinary Incontinence: Rationale for a Non-Randomized Controlled Trial.Osse, NJE., Schonewille, MEA., Engberts, MK., et al.[2023]

References

Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence. [2023]
Urethral Bulkamid® injection after failed midurethral sling: a step-by-step video. [2023]
Comparing Single-Incision Midurethral Sling with Bulking Agents for Female Stress Urinary Incontinence: Rationale for a Non-Randomized Controlled Trial. [2023]
Particulate Versus Non-Particulate Bulking Agents In The Treatment Of Stress Urinary Incontinence. [2023]
Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. [2015]
A diagnostic conundrum: Is it a periurethral diverticulum/cyst or a bulking agent (Bulkamid)? [2023]
Bulkamid (PAHG) in mixed urinary incontinence: What is the outcome? [2018]
Modification of silicone elastomers with Bioglass 45S5® increases in ovo tissue biointegration. [2020]
Poly (caprolactone) microparticles and chitosan thermogels based injectable formulation of etoricoxib for the potential treatment of osteoarthritis. [2018]
Bone healing process in critical-sized defects by rhBMP-2 using poloxamer gel and collagen sponge as carriers. [2008]
11.United Statespubmed.ncbi.nlm.nih.gov
Soft tissue response to glycerol-suspended controlled-release glass particulate. [2019]
12.United Statespubmed.ncbi.nlm.nih.gov
Preparation and characterization of trace elements-multidoped injectable biomimetic materials for minimally invasive treatment of osteoporotic bone trauma. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security